Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). (October 2018)
- Record Type:
- Journal Article
- Title:
- Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). (October 2018)
- Main Title:
- Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
- Authors:
- Vallejo-Vaz, Antonio J.
De Marco, Martina
Stevens, Christophe A.T.
Akram, Asif
Freiberger, Tomas
Hovingh, G. Kees
Kastelein, John J.P.
Mata, Pedro
Raal, Frederick J.
Santos, Raul D.
Soran, Handrean
Watts, Gerald F.
Abifadel, Marianne
Aguilar-Salinas, Carlos A.
Al-khnifsawi, Mutaz
AlKindi, Fahad A.
Alnouri, Fahad
Alonso, Rodrigo
Al-Rasadi, Khalid
Al-Sarraf, Ahmad
Ashavaid, Tester F.
Binder, Christoph J.
Bogsrud, Martin P.
Bourbon, Mafalda
Bruckert, Eric
Chlebus, Krzysztof
Corral, Pablo
Descamps, Olivier
Durst, Ronen
Ezhov, Marat
Fras, Zlatko
Genest, Jacques
Groselj, Urh
Harada-Shiba, Mariko
Kayikcioglu, Meral
Lalic, Katarina
Lam, Carolyn S.P.
Latkovskis, Gustavs
Laufs, Ulrich
Liberopoulos, Evangelos
Lin, Jie
Maher, Vincent
Majano, Nelson
Marais, A. David
März, Winfried
Mirrakhimov, Erkin
Miserez, André R.
Mitchenko, Olena
Nawawi, Hapizah M.
Nordestgaard, Børge G.
Paragh, György
Petrulioniene, Zaneta
Pojskic, Belma
Postadzhiyan, Arman
Reda, Ashraf
Reiner, Željko
Sadoh, Wilson E.
Sahebkar, Amirhossein
Shehab, Abdullah
Shek, Aleksander B.
Stoll, Mario
Su, Ta-Chen
Subramaniam, Tavintharan
Susekov, Andrey V.
Symeonides, Phivos
Tilney, Myra
Tomlinson, Brian
Truong, Thanh-Huong
Tselepis, Alexandros D.
Tybjærg-Hansen, Anne
Vázquez-Cárdenas, Alejandra
Viigimaa, Margus
Vohnout, Branislav
Widén, Elisabeth
Yamashita, Shizuya
Banach, Maciej
Gaita, Dan
Jiang, Lixin
Nilsson, Lennart
Santos, Lourdes E.
Schunkert, Heribert
Tokgözoğlu, Lale
Car, Josip
Catapano, Alberico L.
Ray, Kausik K.
Akram, Asif
Car, Josip
De Marco, Martina
Ray, Kausik K.
Stevens, Christophe A.T.
Vallejo-Vaz, Antonio J.
Corral, Pablo
Schreier, Laura
Watts, Gerald F.
Pang, Jing
Binder, Christoph J.
Dieplinger, Hans
Hanauer-Mader, Gabriele
Descamps, Olivier
Desutter, Johan
Langlois, Michel
Mertens, Ann
Rietzschel, Ernst
Wallemacq, Caroline
Pojskic, Belma
Isakovic, Dzenana
Dzankovic, Amra M.
Obralija, Jasna
Pojskic, Lamija
Sisic, Ibrahim
Stimjanin, Ena
Torlak, Vildana A.
Santos, Raul D.
Jannes, Cinthia E.
Krieger, Jose E.
Pereira, Alexandre C.
Postadzhiyan, Arman
Genest, Jacques
Ruel, Isabelle
Alonso, Rodrigo
Asenjo, Sylvia
Cuevas, Ada
Lin, Jie
Jiang, Lixin
Reiner, Željko
Pećin, Ivan
Symeonides, Phivos
Miltiadous, George
Panayiotou, Andrie G.
Freiberger, Tomas
Vrablik, Michal
Nordestgaard, Børge G.
Tybjærg-Hansen, Anne
Benn, Marianne
Reda, Ashraf
Viigimaa, Margus
Heinsar, Silver
Widén, Elisabeth
Bruckert, Eric
Béliard, S.
Laufs, Ulrich
März, Winfried
Schunkert, Heribert
Gouni-Berthold, Ioanna
Hengstenberg, Wibke
Julius, Ulrich
Kassner, Ursula
Klose, Gerald
König, Christel
König, Wolfgang
Otte, Britta
Parhofer, Klaus
Schatz, Ulrike
Schmidt, Nina
Steinhagen-Thiessen, Elisabeth
Vogt, Anja
Liberopoulos, Evangelos
Tselepis, Alexandros D.
Antza, Christina
Athyros, Vasilios
Bilianou, Eleni
Boufidou, Amalia
Chrousos, George
Elisaf, Moses
Garoufi, Anastasia
Katsiki, Niki
Kolovou, Genovefa
Kotsis, Vasilios
Rallidis, Loukianos
Rizos, Christos
Skalidis, Emmanouel
Skoumas, Ioannis
Tziomalos, Kostantinos
Tomlinson, Brian
Paragh, György
Ashavaid, Tester F.
Shawney, J.P.S.
Sahebkar, Amirhossein
Abbaszadegan, Mohammad R.
Aminzadeh, Majid
Hosseini, Sousan
Mobini, Moein
Vakili, Rahim
Zaeri, Hossein
Al-khnifsawi, Mutaz
Maher, Vincent
Agar, Ruth
Boran, Gerard
Colwell, Nial
Crowley, Vivion
Durkin, Maeve
Griffin, Damian
Kelly, Michael
Rakovac-Tisdall, Ana
Durst, Ronen
Catapano, Alberico L.
Arca, Marcello
Averna, Maurizio
Bertolini, Stefano
Calandra, Sebastiano
Tarugi, Patrizia
Harada-Shiba, Mariko
Yamashita, Shizuya
Al-Sarraf, Ahmad
Mirrakhimov, Erkin
Latkovskis, Gustavs
Erglis, Andrejs
Gilis, Dainus
Nesterovics, Georgijs
Saripo, Vita
Upena-Roze, Arta
Abifadel, Marianne
Elbitar, Sandy
Jambart, Sélim
El Khoury, Petra
Petrulioniene, Zaneta
Gargalskaite, Urte
Kutkiene, Sandra
Nawawi, Hapizah M.
Al-Khatee, Alyaa
An, Chua Y.
Ismail, Zaliha
Kasim, Sazzli
Ibrahim, Khairul S.
Radzi, Ahmad B.M.
Kasim, Noor A.
Nor, Noor S.M.
Ramli, Anis S.
Razak, Suraya A.
Muid, Suhaila
Rosman, Azhari
Sanusi, Abd R.
Razman, Aimi Z.
Nazli, Sukma A.
Kek, Teh L.
Tilney, Myra
Azzopardi, Conrad
Aguilar Salinas, Carlos A.
Vázquez-Cárdenas, N. Alejandra
Galán, Gabriela
Magaña-Torres, M.T.
Martagon, Alexandro
Mehta, Roopa
Hovingh, G. Kees
Kastelein, John J.P.
Wittekoek, M.E.
Sadoh, Wilson E.
Isara, Alphonsus R.
Obaseki, Darlington E.
Ohenhen, Oluwatoyin A.
Bogsrud, Martin P.
Holven, Kirsten B.
Al-Rasadi, Khalid
Santos, Lourdes E.
Banach, Maciej
Chlebus, Krzysztof
Gruchała, Marcin
Baranowska, Marlena
Borowiec-Wolny, Justyna
Gilis-Malinowska, Natasza
Michalska-Grzonkowska, Aleksandra
Pajkowski, Marcin
Parczewska, Aleksandra
Romanowska-Kocejko, Marzena
Stróżyk, Aneta
Żarczyńska-Buchowiecka, Marta
Kleinschmidt, Mariola
Bourbon, Mafalda
Alves, Ana C.
Medeiros, Ana M.
AlKindi, Fahad A.
Gaita, Dan
Ezhov, Marat
Susekov, Andrey V.
Ershova, Alexandra
Korneva, Victoria
Kuznetsova, Tatiana
Malyshev, Pavel
Meshkov, Alexey
Rozhkova, Tatiana
Alnouri, Fahad
Lalic, Katarina
Rajkovic, Natasa
Popovic, Ljiljana
Lukac, Sandra S.
Stosic, Ljubica
Rasulic, Iva
Lalic, Nebojsa M.
Subramaniam, Tavintharan
Lam, Carolyn S.P.
Chua, Terrance S.J.
Ting, Sharon P.L.
Vohnout, Branislav
Raslova, Katarina
Fras, Zlatko
Groselj, Urh
Battelino, Tadej
Cevc, Matija
Jug, Borut
Kovac, Jernej
Podkrajsek, Katarina T.
Sustar, Ursa
Trontelj, Katja J.
Marais, David
Raal, Frederick J.
Mata, Pedro
Perez de Isla, Leopoldo
Nilsson, Lennart
Miserez, André R.
Martin, François J.
Su, Ta-Chen
Charng, Ming-Ji
Chen, Pei-Lung
Kayikçioglu, Meral
Tokgözoğlu, Lale
Mitchenko, Olena
Shehab, Abdullah
Soran, Handrean
Stoll, Mario
Dell'Oca, Nicolás
Fernández, Graciela
Ressia, Andrés
Reyes, Ximena
Zelarayan, Mario
Shek, Aleksander B.
Alieva, Rano B.
Hoshimov, Shavkat U.
Kurbanov, Ravshanbek D.
Nizamov, Ulugbek I.
Majano, Nelson
Lima-Martínez, Marcos M.
Truong, Thanh-Huong
Thi Nguyen, Mai-Ngoc
Do, Doan-Loi
Kim, Ngoc-Thanh
Le, Hong-An
Le, Thanh-Tung
… (more) - Abstract:
- Abstract: Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognisedAbstract: Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. Highlights: The EAS FHSC is an international initiative involving a network of investigators interested in FH from around 70 countries. Information on FH prevalence is lacking in most countries; where available, data tend to align with contemporary estimates. FH diagnosis and management varies widely across countries, with overall suboptimal identification and under-treatment. In most countries diagnosis primarily relies on DLCN criteria, and less frequently on Simon Broom or MEDPED. Therapy for FH is not universally reimbursed, and criteria vary across countries. Access to PCSK9i and apheresis is limited. … (more)
- Is Part Of:
- Atherosclerosis. Volume 277(2018)
- Journal:
- Atherosclerosis
- Issue:
- Volume 277(2018)
- Issue Display:
- Volume 277, Issue 2018 (2018)
- Year:
- 2018
- Volume:
- 277
- Issue:
- 2018
- Issue Sort Value:
- 2018-0277-2018-0000
- Page Start:
- 234
- Page End:
- 255
- Publication Date:
- 2018-10
- Subjects:
- Familial hypercholesterolaemia -- Primary dyslipidaemia -- FHSC
Arteriosclerosis -- Periodicals
Electronic journals
616.136 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00219150 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00219150 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.atherosclerosis.2018.08.051 ↗
- Languages:
- English
- ISSNs:
- 0021-9150
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1765.874000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11279.xml